



Please type a plus sign (+) inside this box → +

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

27

Attorney Docket Number

0230ZQ-087120US

TECH CENTER 1600/2900

OCT 03 2002

RECEIVED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CO, Number of CO(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

Response to Office Action mailed June 24, 2002:
 Amendment (7 pages); Appendix A, Version with Markings to Show Changes Made (1 page), Appendix B, Claims Subject to Examination (2 pages); Exhibit A, Boehringer-Mannheim product information manual (3 pages); Exhibit B, Invitrogen product information on Gateway vectors (3 pages); Exhibit C, Invitrogen product information on Gateway vectors (2 pages); Exhibit D, Roche product Information on MBP fusion vectors (6 pages); Exhibit E, Invitrogen product information on EKMex and EK-Away (2 pages), and Return Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Kevin Bastian	
Signature		
Date	September 24, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231 on this date:

September 24, 2002

Typed or printed name	Jill R. Clarke		
Signature			Date
		September 24, 2002	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
 SF 1388992 v1

8/3
DMJ
18-8-02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Box Non-Fee Amendment, Assistant Commissioner for Patents,
Washington, D.C. 20231



On September 24, 2002

TOWNSENO and TOWNSENO and CREW LLP

By: Jill R. Clarke
Jill R. Clarke

PATENT
Attorney Docket No.: 023070-087120US
Client Ref. No.: 98-005-2

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

VREELAND, Valerie

Application No.: 09/840,762

Filed: April 23, 2001

For: RECOMBINANT VANADIUM
HALOPEROXIDASES AND THEIR
USES

Examiner: PATTERSON, CHARLES
L., JR

Art Unit: 1652

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed June 24, 2002, please amend the claims as follows. Applicants respectfully request that the Examiner reconsider the claims in the light of the amendment and the following remarks. Appendix A is a marked-up version showing all changes made. Appendix B shows all claims subject to examination after entry of the present amendment.

IN THE CLAIMS:

Please cancel claims 18 and 19.

Please substitute claim 16 with the following clean, amended version:

16. (Amended) An isolated polypeptide comprising an amino acid

sequence having at least 90% amino acid sequence identity to a sequence from residue

(3)